Replies to post #122525 on Biotech Values

[DewDiligence]

It will be interesting to see what the FDA does with respect to the two doses for DME. Based on the data in #msg-64703260, the FDA can’t simply disregard the 0.3mg data as they did in the AMD label (#msg-11842516).

[DewDiligence]

UK’s NICE rejects Lucentis coverage for DME even though they cover it for AMD:

http://www.reuters.com/article/2011/07/14/novartis-britain-lucentis-idUSL6E7IE1YY20110714

Go figure.